Dihexa Dosage Guide: Cognitive Peptide, Memory Support & Neuroplasticity Protocol
Dihexa
Dihexa is a synthetic angiotensin IV-derived compound studied primarily for its effects on synaptic connectivity, memory-related pathways, and HGF/c-Met signaling. Preclinical studies have reported procognitive and synaptogenic effects in laboratory and animal models, but human clinical efficacy, dosing, and long-term safety have not been established.
Important Distinction
Dihexa is an angiotensin IV-derived research compound rather than a traditional injectable peptide.
It is commonly discussed in oral research-use formats.
Bacteriostatic-water reconstitution is not part of the oral framework shown on this page.
Oral amounts are measured in milligrams rather than mcg or insulin-syringe units.
No standardized human oral dosing regimen has been established.
How It Works
HGF/c-Met Signaling → Synaptogenesis Research → Memory + Cognitive Research
Dihexa binds hepatocyte growth factor (HGF) and potentiates HGF-dependent activation of the c-Met receptor. Preclinical studies have linked this pathway with hippocampal spinogenesis, synapse formation, and memory-related effects, but these findings have not been validated as clinical cognitive benefits in humans.
Dihexa Research-Use Protocol
Gradual Cognitive Support → Synaptic Signaling ↑ → Memory + Learning Support
Weeks 1–2
Starting Phase
Dose5–10 mg daily
Weeks 3–8
Build Phase
Dose10–20 mg daily
Protocol Details
FrequencyOnce daily
TimingMorning preferred
RouteOral (research use)
Research-Use Cycle4–8 weeks
Simple Approach:
Dihexa research-use frameworks commonly begin with lower oral amounts before considering increases. Because human dose-finding studies have not established an optimal range, higher amounts should not automatically be assumed to produce stronger cognitive effects.
Dihexa research-use frameworks commonly begin with lower oral amounts before considering increases. Because human dose-finding studies have not established an optimal range, higher amounts should not automatically be assumed to produce stronger cognitive effects.
Advanced Approach
Higher Range
Higher Research-Use Range
Dose20–30 mg daily
Higher Research-Use Range:
Higher oral amounts are sometimes discussed in research-use settings, but human dose-response and safety data have not been established. Higher exposure should not automatically be interpreted as producing greater cognitive or synaptogenic effects.
Higher oral amounts are sometimes discussed in research-use settings, but human dose-response and safety data have not been established. Higher exposure should not automatically be interpreted as producing greater cognitive or synaptogenic effects.
When & How to Use
Once daily oral use
Morning dosing preferred for cognitive support
Maintain consistent daily timing
Monitor cognitive and neurological response
Areas of Research Interest
HGF / c-Met signaling research
Synaptogenesis and neural-connectivity research
Memory and learning models
Neurodegenerative-disease research
Experimental cognitive and neuroplasticity research
Administration & Storage
FormOral / research compound
ReconstitutionNot required
UseOnce daily
Storage
Store in a cool, dry place
Protect from heat, moisture, and light
Keep sealed to prevent degradation
Cycle Length & Time Between Cycles
Cognitive Support Phase → Break → Reassess → Repeat if Needed
Cycle Structure
Research-Use Cycle4–8 weeks
Commonly Discussed Break2–4 weeks
Use StyleShort cycles preferred
Clinical Standard
No established human cycle or required off-period
Research context:
The cycle and break shown here are research-use frameworks rather than clinically established requirements. Human studies have not established an optimal Dihexa treatment duration or required washout period.
The cycle and break shown here are research-use frameworks rather than clinically established requirements. Human studies have not established an optimal Dihexa treatment duration or required washout period.
Monitoring During Use
Memory and recall
Focus and cognitive clarity
Mood and mental energy
Sleep quality and overstimulation
Benefits
Preclinical research has demonstrated HGF / c-Met-dependent synaptogenic activity
Animal studies have reported improvements in memory-related performance
Laboratory research has demonstrated hippocampal spinogenesis and synapse formation
Dihexa remains an experimental compound in neuroplasticity and neurodegeneration research
Human cognitive benefits have not been established in controlled clinical trials
Potential Side Effects
Human adverse-effect frequency has not been established
Neurologic, cognitive, mood, or sleep response may vary between individuals
Human safety data remain extremely limited
Long-term safety of repeated oral research-use cycles has not been established
Potential consequences of prolonged HGF / c-Met pathway modulation remain uncertain
Important Notes
Dihexa is an angiotensin IV-derived experimental compound studied primarily in laboratory and animal research.
Its best-characterized mechanism involves potentiation of HGF/c-Met signaling and associated synaptogenic activity. However, several of the foundational publications behind this proposed mechanism were later retracted or received expressions of concern, creating uncertainty around parts of the pathway itself.
Its best-characterized mechanism involves potentiation of HGF / c-Met signaling and associated synaptogenic activity.
Published evidence for cognitive and memory-related effects remains preclinical.
No standardized human dose, cycle length, maintenance regimen, or required off-period has been established.
The 5–30 mg oral ranges shown on this page are research-use frameworks rather than validated clinical dosing guidelines.
Long-term human safety, drug-interaction, and HGF / c-Met pathway safety data remain limited.
Important Disclaimer
Dihexa is an investigational compound and is not FDA-approved. This content is for educational and research purposes only.
Research & References
Primary Research
- McCoy AT, Benoist CC, Wright JW, et al. Evaluation of Metabolically Stabilized Angiotensin IV Analogs as Procognitive/Antidementia Agents. J Pharmacol Exp Ther. 2013. (Foundational paper introducing Dihexa and related stabilized AngIV analogs.)
- Sun X, Deng Y, Fu X, et al. AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway. Brain Sciences. 2021.
Reviews & Supporting Research
- Wright JW, Harding JW. The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer's Disease. Journal of Alzheimer's Disease. 2015. (Review of the HGF/c-Met mechanism proposed for Dihexa.)
Research Note: Dihexa is one of the most discussed experimental cognitive peptides, but its evidence base is considerably weaker than many online discussions suggest. Nearly all published efficacy data comes from cell culture and animal studies, with no controlled human clinical trials evaluating safety or effectiveness. Several foundational mechanistic publications related to Dihexa's proposed AngIV/HGF pathway were later retracted or received expressions of concern, creating uncertainty around parts of the proposed mechanism. Dosing protocols circulating online are not derived from clinical dosing studies and should be treated as unverified.
Comments
Post a Comment